In CRC, inhibition of NETs with DNase I results in the reversal of anti-PD-1 blockade resistance [63]; thus, exploring the relationship between NETs and adaptive immunity may provide novel ideas for tumor therapy. This evidence concerns the gene DNASE1 and colorectal carcinoma.